Managers / Q4 2025 · view latest →
Andera Partners
CIK 0001757283 · 2, PLACE RIO DE JANEIRO, PARIS, 75008 · 33 1 85 73 64 00
Summary
Andera Partners reported $177M in U.S.-listed holdings across 5 positions for Q4 2025.
The portfolio is heavily concentrated: Kestra Med Technologies alone accounts for 38.1% of reported value.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 51.1% · $90M
- Other · 38.1% · $67M
- ADR · 10.8% · $19M
Quarter-over-Quarter Changes full breakdown →
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| KESTRA MED TECHNOLOGIES LTD | NEW | +2.54M | 2.54M | +$67M | $67M |
| MLYSMINERALYS THERAPEUTICS INC | NEW | +1.59M | 1.59M | +$58M | $58M |
| EVMNEVOMMUNE INC | NEW | +1.90M | 1.90M | +$32M | $32M |
| ABVXABIVAX SA | NEW | +78.1K | 78.1K | +$11M | $11M |
| IVAINVENTIVA SA | NEW | +1.82M | 1.82M | +$8M | $8M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2025
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | KESTRA MED TECHNOLOGIES LTD | SHS | 38.14% | $67M | 2.54M |
| 2 | MLYSMINERALYS THERAPEUTICS INChistory → | COM | 32.71% | $58M | 1.59M |
| 3 | EVMNEVOMMUNE INChistory → | COM SHS | 18.39% | $32M | 1.90M |
| 4 | ABVXABIVAX SAhistory → | SPONSORED ADS | 5.97% | $11M | 78.1K |
| 5 | IVAINVENTIVA SAhistory → | ADS | 4.79% | $8M | 1.82M |
Filing History
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.